Biomedical subjects

Toru Taniguchi

Publications and source records attributed to Toru Taniguchi.

4 recordsLinked to original sources

PubMed2006

Aqueous humor dynamics associated with the phorbol ester-induced decrease in intraocular pressure in the rabbit.

PURPOSE: To determine the effects of injection of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) into the anterior chamber of the eye on intraocular pressure (IOP) and aqueous humor dynamics. METHODS: IOP was measured for 24 h after intracameral injection of PMA (3 to 50 pmol) in unanesthetized rabbits. Aqueous humor dynamics (aqueous flow, total outflow facility, and uveoscleral outflow) were determined approximately 6 h after injection of 50 pmol of PMA in animals pretreated with indomethacin. RESULTS: Intracameral injection of 50 pmol of PMA induced a biphasic effect on IOP, consisting of a transient increase apparent at 0.5 and 1 h and a sustained decrease apparent after 2 h. This effect of PMA was dose dependent. Whereas pretreatment with indomethacin attenuated the PMA-induced increase in IOP, the sustained decrease in IOP remained apparent in the pretreated rabbits. Intracameral injection of 4alpha-PMA, an inactive PMA analog, had no effect on IOP. PMA also significantly increased uveoscleral outflow, but it had no effect on aqueous flow or total outflow facility. CONCLUSION: Intracameral injection of PMA reduced IOP in the rabbits by increasing the rate of uveoscleral outflow. This IOP-lowering effect of PMA may be mediated by activation of PKC.

Animals↗

PubMedDate not supplied

Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients.

PURPOSE: The amount of intraocular pressure (IOP) reduction achieved by the use of latanoprost eyedrops varies among patients, and there are even nonresponders. This report examines whether there is any correlation between the amount of individual variability in IOP reduction and the uveoscleral outflow facility after latanoprost eyedrop instillation in normal-tension glaucoma patients. METHODS: Sixteen normal-tension glaucoma patients (mean age, 56.4 years) were enrolled in the study to investigate the relationship between the amount of IOP reduction and outflow facility. Before treatment, subjects underwent circadian IOP measurement and then tonography, and the outflow facility was calculated. Subsequently, patients began treatment once daily with latanoprost instillation in one eye. After 4 weeks of daily latanoprost treatment, circadian IOP was measured again. RESULTS: Mean pretreatment outflow facility was 0.23 +/- 0.05 microl/min per mmHg. On average, latanoprost instillation decreased IOP by 2.8 mmHg, but the reduction varied among individuals from -0.3 mmHg to 5.8 mmHg. No significant correlation was noted between the outflow facility and the IOP decline associated with latanoprost. CONCLUSION: Because there was no significant correlation between individual IOP reduction by latanoprost and outflow facility, the differences in substantial change in uveoscleral outflow after latanoprost administration may be one explanation for the individual variation in IOP reduction after treatment with this drug.

Adult↗

PubMedDate not supplied

Ultrasound biomicroscopic classification of zonules in exfoliation syndrome.

PURPOSE: Exfoliation changes in the zonules or ciliary processes may be the earliest clinical sign of the exfoliation syndrome (XFS). In the present study we investigated the usefulness of ultrasound biomicroscopy (UBM) for detecting the early changes of XFS in zonules. METHODS: Both eyes of 11 patients with unilateral XFS and the unilateral eyes of 11 subjects without evidence of XFS were examined using UBM. The incidence of zonular changes was compared among the XFS-positive eyes of the patients, their contralateral XFS-negative eyes, and the healthy eyes of the subjects without XFS. RESULTS: Using UBM, we could successfully describe the zonules in all UBM images of all subjects. In the four quadrants, the incidence of granular-type zonules was statistically different among the three groups: it was higher in XFP-positive eyes than in XFS-negative eyes, and it was higher in XFS-negative eyes than in healthy eyes. CONCLUSIONS: UBM can detect the zonular changes that may occur early in XFS. A granular-type change in the zonules may be the most typical finding in the presence of exfoliation material. Diagnostic criteria are proposed for the early detection of XFS, based on the changes found in the zonules by UBM.

Aged↗

PubMedDate not supplied

Neuroprotective effects of R(-)-1-(benzo[b]thiophen-5-yl)-2- [2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588) against retinal ganglion cell death induced by elevated intraocular pressure in rat.

PURPOSE: We investigated whether T-588 can attenuate retinal ganglion cell (RGC) death induced by elevated intraocular pressure (IOP). METHODS: IOP elevation was induced unilaterally by argon laser irradiation of the rat trabecular meshwork 4 days after an intracameral injection of India ink. We orally administered either the vehicle, or 10, 30, or 100 mg/kg body weight (BW) of T-588 24 hours before the laser application. Five days after the laser application, 1.5 microL of 3% Fast Blue was injected into the superior colliculi bilaterally. Three days after the Fast Blue injection, the eye was enucleated and the retinal whole flatmount was prepared. Labeled ganglion cells were counted by fluorescence microscope with an ultraviolet filter. RESULTS: Laser treatment significantly increased the IOP. The percentages of labeled RGCs in the lasered eyes as compared with the nonlasered contralateral eyes were 78.0 +/- 11.6% in the control group, 78.7 +/- 12.9% in the 10 mg/kg BW group, 79.1 +/- 13.0% in the 30 mg/kg BW group, and 91.0 +/- 9.0% in the 100 mg/kg BW T-588-treated group. The survival rate of RGCs was significantly higher in the 100 mg/kg BW T-588-treated group than in the control group. CONCLUSION: T-588 appears to have a neuroprotective effect on retinal ganglion cells in this ocular hypertensive model.

Administration, Oral↗